- Last edited on December 13, 2021
Vortioxetine (Trintellix/Brintillex)
Primer
Vortioxetine (Trade name: Trintellix/Brintillex) is an antidepressant in the serotonin modulator and stimulator class used in the treatment of major depressive disorder.
Pharmacokinetics
See also article: Introduction to Pharmacology
Pharmacokinetics of Vortioxetine
Absorption | |
---|---|
Distribution | |
Metabolism | |
Elimination | |
Half-life | 57 hours |
See also article: Cytochrome (CYP) P450 Metabolism
Vortioxetine: Cytochrome P450 Metabolism
Substrate of (Metabolized by) | |
---|---|
Induces | |
Inhibits |
Pharmacodynamics
Mechanism of Action
- Similar vilazodone, vortioxetine acts like an SSRI but also has direct serotonin receptor interactions that is thought to theoretically add to its clinical benefit. It has the following actions:
- Serotonin (5-HT) transporter (SERT) inhibition
- Serotonin (5-HT) receptor agonism:
- 5-HT1A agonism
- Which theoretically can enhance downregulation of presynaptic 5-HT1A receptors and lead to more robust disinhibition of serotonin release
- Serotonin (5-HT) receptor partial agonism:
- 5-HT1B partial agonism
- Thought to have potential antidepressant effects.[1]
- Serotonin (5-HT) receptor antagonism:
- 5-HT3 antagonism
- 5-HT1D antagonism
- Thought to have impact on anxiety and vascular vasoconstriction in the brain.
- 5-HT7 antagonism
- Is thought give pro-cognitive effects (not clinically proven, nor approved by FDA!)
Toxicity
- Vortioxetine is relatively non-toxic in overdose
Indications
- Major depressive disorder
- Anxiety disorders
Dosing
Dosing for Vortioxetine
Starting | 10 mg |
---|---|
Titration | Increase by another 10 mg after 1 to 2 weeks, depending on tolerability |
Maximum | 20 mg |
Taper | Long-half life, self-tapering, no withdrawal side effects |
Formulations
- Vortioxetine comes in an oral formulation
Monitoring
Contraindications
Absolute
Relative
Drug-Drug Interactions
Side Effects
- Nausea (more so than other SSRIs), vomiting, constipation; possibly less sexual SE, sedation and weight gain
Cognition
- Currently marketed by pharmaceutical companies as having more improvement on cognitive effects of depression (but this claim is very questionable).
- This marketing strategy was based on studies showing slightly better performance on the digit substitution test, which is only a single domain test, and not a comprehensive cognitive assessment.[4]
- The FDA in fact rejected the drug manufacturer’s request to claim that vortioxetine improved cognition in depression based on this poor quality study data.[5]
- However, the drug company Lundbeck decided to market it saying it is “the first FDA-approved treatment for MDD to have data in the U.S. Prescribing Information showing a positive effect on processing speed.”[6]
- Importantly, this is not the same as having FDA approval to market the drug for the actual treatment of cognitive dysfunction in depression!
Adverse Events
Clinical Pearls
Special Populations
Geriatric
See main article: Geriatric Pharmacology
Pediatric
See main article: Pediatric Pharmacology
Obstetric and Fetal
See main article: Obstetric and Fetal Pharmacology
Medically Ill
See main article: Psychotropic Dosing in the Medically Ill
Resources
References
1)
Tiger, M., Varnäs, K., Okubo, Y., & Lundberg, J. (2018). The 5-HT 1B receptor-a potential target for antidepressant treatment. Psychopharmacology, 235(5), 1317-1334.
2)
Wagner, G., Schultes, M. T., Titscher, V., Teufer, B., Klerings, I., & Gartlehner, G. (2018). Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. Journal of affective disorders, 228, 1-12.
3)
Aydin, O., & Ünal-Aydin, P. (2017). Vortioxetine-induced nausea and its management. Psychiatry and Clinical Psychopharmacology, 27(3), 325.